Your session is about to expire
← Back to Search
ONS-5010 bevacizumab for Age-Related Macular Degeneration
Study Summary
This trial is a study that will test the safety and effectiveness of a medication called ONS-5010 when it is given directly into the eye. The study will be conducted at multiple locations and participants
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 1 & 2 trial • 96 Patients • NCT01266031Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available openings for patients to participate in this medical study?
"Indeed, according to the information available on clinicaltrials.gov, this trial is actively seeking eligible candidates. The initial posting of the trial occurred on January 24th, 2024 and it was last edited on January 25th, 2024."
How large is the participant pool in this particular research endeavor?
"Indeed, as mentioned on clinicaltrials.gov, this ongoing clinical trial is presently enrolling patients. The study was initially posted on January 24th, 2024 and last updated on January 25th, 2024. It aims to enroll a total of 400 participants from one designated location."
Has ONS-5010 bevacizumab received official endorsement by the FDA?
"The safety rating for ONS-5010 bevacizumab is assigned a score of 3 by our team at Power. This classification reflects the fact that this trial has progressed to Phase 3, indicating previous evidence supporting its effectiveness and multiple rounds of data affirming its safety."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger